Skip to main content

Advertisement

Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease

Fig. 5

Association of kallikrein 6 (KLK6) to apolipoprotein E (APOE) ε4 status, clinical diagnosis and core Alzheimer’s disease (AD) biomarker profile in cohort 2. a Box plot of plasma KLK6 in non-carriers (yellow box) and APOE ε4 carriers (orange box). b Box plot of cerebrospinal fluid (CSF) KLK6 in non-carriers (light blue box) and APOE ε4 carriers (dark blue box). c Bivariate plots showing correlations between plasma (upper panels) and CSF (lower panels) with Mini Mental State Examination (MMSE) scores, total tau (t-tau), phosphorylated tau (p-tau), amyloid-β 1–42 (Aβ42) and amyloid-β 1–40 (Aβ40). Open dots = control subjects; green dots = patients with mild cognitive impairment that remained unchanged over 24 months; blue dots = patients with mild cognitive impairment who developed Alzheimer’s disease; red dots = AD. NS Not significant

Back to article page